Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > ARCHIVE
ARCHIVE
- Chugai to Apply for Xeloda Based on Data from Public Domain
September 20, 2010
- Shionogi Licenses 2 SLIT Tablets from Stallergenes
September 20, 2010
- Ancaron Approved for Additional Indication Based on Data from Public Domain
September 20, 2010
- ViiV to Continue Its Commitment to HIV Area: President Iriyama
September 20, 2010
- Multaq Recommended as First-Line Option for AF in ESC GL
September 20, 2010
- Bayer to Embark on Esthetic Dermatology Business
September 20, 2010
- Earlier Access to Unapproved Drugs Proposed at Chuikyo
September 20, 2010
- Overall Price Settlement Rate at 28.1% as of the End of June
September 20, 2010
- Pfizer to Undertake Development of Injectable Metronidazole
September 20, 2010
- JMHA to Jointly Purchase Drugs
September 20, 2010
- Takara Bio Licenses Nucleic Acid Refining Reagent from Macherey-Nagel
September 20, 2010
- Eisai Launches Glufast in China
September 20, 2010
- Rivaroxaban Non-Inferior to Standard Therapy: Bayer
September 20, 2010
- Sawai Prepares for Biosimilars Business
September 20, 2010
- Apixaban More Effective than Aspirin in AF: BMS/Pfizer
September 20, 2010
- Sandoz to Expand Range of Target Doctors for Somatropin Biosimilars
September 20, 2010
- JSNM to Promote Use of PET Drugs for Drug Discovery
September 20, 2010
- Humira Applied for JIA in Japan: Abbott, Eisai
September 13, 2010
- No Significant Differences in ADRs between Avandia, Actos: HealthCore
September 13, 2010
- Korosho Demands Budgets to Develop Buried Seeds of Drugs
September 13, 2010
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…